CellPhire
- Company typePrivate
- Founded2014
- HeadquartersRockville, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
CellPhire firmographics
Firmographics- Name
- CellPhire
- Legal name
- Cellphire, Inc.
- Website
- https://cellphire.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
CellPhire industry classification
Industry- Product category
- Platelet-Derived Biologic Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Blood and Organ Banks (621991)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB)
- akta.pro secondary industries
- Platelet-Rich Plasma (PRP) & Blood-Derived Orthobiologics (HLAMANAB), Cryopreservation, Biobanking & Cell Banking (Cord/Adipose/MSC) (HLAMANAJ), Stem Cell Therapies (Autologous & Allogeneic) (HLAMANAA), Lyophilization (Freeze-Drying) CDMO (HLAGABAI), Fibrin Sealants & Plasma-Derived Surgical Hemostats (Fibrinogen/Thrombin) (HLAIAHAG)
Keywords
Where CellPhire is headquartered
LocationHeadquarters
- HQ city
- Rockville
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
CellPhire business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Biopharmaceutical Product Revenue: As a pre-revenue clinical-stage biotechnology company, Cellphire does not yet generate product revenue. The company is advancing its platelet-derived biologic pipeline toward regulatory approval (BLA). CLPH-511 targets BLA filing in 2026. Revenue will ultimately come from commercial sales of CLPH-511 (cryopreserved platelets) and FPH platform products (CLPH-211, CLPH-251) upon FDA approval. The company also operates a veterinary subsidiary BodeVet with a commercially available canine product (StablePlate RX).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | — | Pre-commercial / Investigational Products |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels6 records
CellPhire product offering
Product offeringCore offering
Cellphire develops stabilized, allogeneic, platelet-derived cellular therapeutics through two proprietary platforms: CLPH-511 cryopreserved platelets with a 5-year frozen shelf life, and the FPH/Thrombosomes freeze-dried platelet-derived hemostat with 3+ year room temperature stability. Both products are manufactured from pooled, irradiated, leukocyte-reduced Group O donor apheresis platelets. The company also operates a veterinary subsidiary (BodeVet) commercializing a canine freeze-dried platelet product.
Product overview
Cellphire Therapeutics is a clinical-stage biotechnology company developing a portfolio of next-generation allogeneic, stabilized platelet-derived cellular therapeutics. The company operates two core technology platforms: Cryopreserved Platelets (CLPH-511) with 5-year frozen shelf life and the FPH (Freeze-dried Platelet-derived Hemostat) platform (CLPH-211, CLPH-251, CLPH-291) with 3+ year room temperature stability. CLPH-511 is the lead product in Phase 2/3 clinical trials for acute hemorrhage, while CLPH-211 is advancing in Phase 2 studies for perioperative bleeding. A discovery-stage drug delivery platform (CLPH-701) explores loading therapeutic molecules into stabilized platelets. The company also operates BodeVet, a veterinary subsidiary commercializing freeze-dried platelet products for animals.
Differentiator
Problem solved
Functional benefit
Brands
- BodeVet: Veterinary subsidiary developing and commercializing transfusion medicine therapies for companion animals including StablePlate RX Canine freeze-dried platelet product for dogs.
- Thrombosomes
Products and services
- CLPH-511 (Cryopreserved Platelets / CPP) CLPH-511 is a frozen, activated platelet product for IV use with a 5-year shelf life stored at ≤-65°C. Manufactured from pooled, irradiated, leukocyte-reduced apheresis platelets from up to 10 Group O donors, concentrated with DMSO cryoprotectant before freezing. Thawing and resuspension takes approximately 15 minutes. It is being developed for acute hemorrhage as an alternative to conventional liquid stored platelets when not available or in short supply. CRYPTICS Phase 2/3 trial was stopped early for efficacy after 150+ subjects.
- CLPH-211 (FPH / Thrombosomes) CLPH-211 (marketed as Thrombosomes) is a freeze-dried platelet-derived hemostatic agent with 3+ year room temperature shelf life. Manufactured by pooling platelets from 10 Group O donors, removing plasma, loading trehalose as a stabilizer, and freeze-drying. Rehydrated with sterile water in minutes for systemic hemostatic use in uncontrolled perioperative bleeding, either alone or as adjunct therapy. Heat-treated for pathogen reduction with 70+ human exposures and positive safety data.
- CLPH-251 (FPH for TBI/ICH) CLPH-251 is an FPH platform product in pre-IND stage for treatment of Traumatic Brain Injury (TBI) with acute hemorrhage and spontaneous Acute Intracerebral Hemorrhage (sICH). It has potential to stop hemorrhage, prevent hematoma volume expansion, and reduce secondary injury. Approximately 1.4 million individuals incur TBI in the US annually with 90,000 experiencing long-term disabilities.
- CLPH-291 (FPH Pipeline Product) CLPH-291 is a freeze-dried platelet-derived hemostatic product in development as part of the FPH platform family. It is positioned as a pipeline product leveraging the company's core freeze-drying and trehalose stabilization technology.
- CLPH-701 (Platelet-Enabled Drug Delivery) CLPH-701 is a discovery-stage platform technology for loading and stabilizing different types of biologic molecules into platelets for targeted drug delivery. Applications include oncology, tumor metastasis, cardiac ischemia, RNA/miRNA delivery, and innate immunity. The technology uses the company's proprietary platelet stabilization methods to create drug-loaded platelet products.
- StablePlate RX Canine StablePlate RX Canine is a commercially available canine freeze-dried platelet product with demonstrated efficacy in stopping bleeding in dogs. Developed and marketed by BodeVet, Cellphire's veterinary subsidiary, with expansion underway to support equine patients and exotic animals such as elephants.
Quantifiable outcome
- CRYPTICS trial met primary efficacy endpoint: 24-hour chest tube drainage difference in LS Means was 142.0 mL (95.576% CI lower than non-inferiority margin); p-value < 0.00965; trial stopped early for efficacy after >150 subjects.
- +4 more outcomes
Companies that use CellPhire
Customer profileNamed customers10 records
Segments6 records
Ideal customer profiles4 records
CellPhire technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
CellPhire partnerships and signals
Strategic signalPartnerships
14 partnerships are on record, tiered core and minor.
- VitalantcoreStrategic partnership with Vitalant, one of the nation's largest nonprofit blood and biotherapies healthcare organizations. The partnership includes an initial investment by Vitalant and support for Cellphire's product development and clinical manufacturing processes of its freeze-dried platelet derived hemostat (FPH) and Cryopreserved Platelets (CPP). Vitalant serves as a critical supplier for Cellphire's product development and clinical manufacturing.
- Medical Technology Enterprise Consortium (MTEC)minorConsortium partner supporting medical technology development for military applications.
- University of California San Francisco (UCSF)coreAcademic collaborator conducting preclinical research demonstrating vascular repair and neuroprotective effects of platelet-derived biologic in traumatic brain injury. Study published in Blood journal (April 2026). Joint research on Ang1-Tie2 signaling pathway activation.
- Rigshospitalet Copenhagen University HospitalcorePrincipal investigator-initiated trial site for Thrombosomes (FPH) in Acute Thoracic Aortic Dissections (TTAD). Dr. Jakob Stensballe and Dr. Annette Ulrich led enrollment of 41 patients, completing ahead of schedule. Supported by Danish clinical research infrastructure.
- Weill Cornell MedicineminorAcademic partner in Cellphire's network of research universities advancing development of stabilized cellular therapies.
- University of MarylandminorAcademic partner and clinical trial site (University of Maryland Medical Center) participating in CRYPTICS Phase 2/3 study.
- Johns Hopkins UniversitycoreClinical trial site (Johns Hopkins Hospital) for CRYPTICS study; Dr. Glenn Whitman presented CRYPTICS topline data at 2025 AABB Annual Meeting. Advisory board member Dr. Glen Whitman serves as Director of CV Surgical ICU and Professor of Cardiac Surgery.
- Dana-Farber Cancer Institute / Harvard Medical SchoolminorScientific advisor Dr. Jose A. Cancelas serves as Executive Director at Connell and O'Reilly Families Cell Manipulation Core Facility at Dana-Farber, providing scientific guidance on transfusion medicine and cell therapies.
- Georgetown UniversityminorAcademic partner with MedStar Georgetown University Hospital serving as a clinical trial site for Thrombosomes Phase 2 study.
- MD Anderson Cancer CenterminorClinical trial site for Thrombosomes Phase 2 study in bleeding thrombocytopenic patients.
- City of HopeminorClinical trial site for Thrombosomes Phase 2 study.
- Vanderbilt Medical CenterminorClinical trial site for Thrombosomes Phase 2 study and CRYPTICS Phase 2/3 study.
- Kansas State UniversityminorAcademic collaborator in Cellphire's research network.
- BodeVetminorVeterinary subsidiary of Cellphire developing and commercializing companion animal transfusion medicine products including StablePlate RX Canine. Expanding to equine and exotic animal applications.
Scale indicators16 records
Recent moves6 records
Expansion highlights6 records
CellPhire competitors and assessment
Company assessmentDirect peers
- Velico Medical: Velico is developing spray-dried plasma products for hemostatic and trauma use, including products targeting emergency and military settings. It is a direct peer in the stabilized/lyophilized blood product space where shelf life and rapid reconstitution are critical.
- Cerus Corporation: Cerus develops INTERCEPT, a pathogen-reduction system for platelets and other blood components. As a direct peer in the platelet safety/supply space, Cerus is highly comparable to Cellphire in addressing limitations of conventional platelet storage and transfusion safety.
Emerging players
- Medcura: Medcura develops hemostatic products for surgical, trauma, and consumer applications using proprietary biopolymer technology. It is an emerging player in the bleeding management space with overlapping surgical and trauma use cases.
- Cresilon: Cresilon develops hemostatic gel technology (Veti-Gel) for rapid bleeding control in trauma, surgical, and veterinary settings. It is an emerging player in the broader hemostasis market with overlapping customer segments (trauma, surgical, veterinary) and product positioning.
- Lineage Cell Therapeutics: Lineage Cell Therapeutics is an allogeneic cell therapy developer with a multi-platform pipeline addressing ophthalmology, oncology, and neurological indications. It is an emerging player in the allogeneic, off-the-shelf cell therapy space that shares the platform-based, multi-indication approach that defines Cellphire's platelet-derived pipeline.
- Pluristem Therapeutics: Pluristem is developing off-the-shelf allogeneic cell therapy products from placental cells for hematology, inflammation, and ischemia indications. It is an emerging player in the allogeneic cell therapy space with a similar platform-approach to addressing multiple indications from a single manufacturing process.
Broad incumbents
- Grifols: Grifols is a global leader in plasma-derived therapies and blood products, including platelet-related fractionation and transfusion products. As a broad incumbent, it has the scale, regulatory relationships, and commercial reach that any successful stabilized platelet therapy would eventually compete against.
- Terumo BCT: Terumo BCT is a global leader in blood component collection, processing, and storage technologies, including platelet apheresis systems. It is a broad incumbent supplying the equipment and consumables underpinning the platelet supply chain that Cellphire's technology ultimately serves.
- Octapharma: Octapharma is a major human protein products manufacturer with a portfolio that includes coagulation and hemostasis products. It is a broad incumbent in the blood-derived therapeutics space with overlapping indications (perioperative bleeding, hemophilia).
- CSL Behring: CSL Behring is a global leader in plasma-derived and recombinant therapeutic proteins, including products for hemostasis, coagulation, and critical care. It is a broad incumbent with deep relationships in hospital transfusion medicine and trauma care.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
CellPhire social profiles
Digital presenceCellPhire financial estimates
Financial estimateRevenue estimate
Valuation estimate
CellPhire leadership team
Management profileNumber of profiles
Profiles9 records
CellPhire subsidiaries and ownership
Company hierarchySubsidiaries1 record
CellPhire funding detail
Funding detailFunding overview
Funding rounds4 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CellPhire M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CellPhire
What does CellPhire do?
Cellphire develops stabilized, allogeneic, platelet-derived cellular therapeutics through two proprietary platforms: CLPH-511 cryopreserved platelets with a 5-year frozen shelf life, and the FPH/Thrombosomes freeze-dried platelet-derived hemostat with 3+ year room temperature stability. Both products are manufactured from pooled, irradiated, leukocyte-reduced Group O donor apheresis platelets. The company also operates a veterinary subsidiary (BodeVet) commercializing a canine freeze-dried platelet product.
Is CellPhire a public or private company?
CellPhire is a private company. It is classified as venture growth investor backed and is currently operating.
When was CellPhire founded?
CellPhire was founded in 2014. It employs 11 to 50 people.
Where is CellPhire based?
CellPhire is headquartered in Rockville, United States, in the North America region.
How does CellPhire make money?
One revenue line is on record: biopharmaceutical Product Revenue.
Who are CellPhire's main competitors?
Direct peers on record are Velico Medical and Cerus Corporation. Emerging players are Medcura, Cresilon, Lineage Cell Therapeutics and Pluristem Therapeutics. Broad incumbents are Grifols, Terumo BCT, Octapharma and CSL Behring.
Does CellPhire have an API?
No public API is recorded for CellPhire.
What industry is CellPhire in?
CellPhire's product category is Platelet-Derived Biologic Therapeutics. Its primary akta.pro industry code is HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf), with a secondary code of HLAMANAB, Platelet-Rich Plasma (PRP) & Blood-Derived Orthobiologics. Its NAICS code is 325414 and its SIC code is 2836.